Published in Oncol Lett on October 19, 2016
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Apoptosis: a review of programmed cell death. Toxicol Pathol (2007) 17.92
Proliferation, cell cycle and apoptosis in cancer. Nature (2001) 9.57
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol (2004) 4.37
Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene (2001) 3.83
From bench to clinic with apoptosis-based therapeutic agents. Nature (2000) 2.96
Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell (2014) 2.74
AP-1--The Jun proteins: Oncogenes or tumor suppressors in disguise? Cell Signal (2010) 2.49
Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park) (2014) 2.48
A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med (2012) 1.84
Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell (2001) 1.79
Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev (2005) 1.42
Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer (2006) 1.22
c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol Cell Biol (2000) 1.18
Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors. Mol Cell Biol (2000) 1.15
c-Jun, at the crossroad of the signaling network. Protein Cell (2011) 1.14
MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget (2014) 1.06
Target therapies in pancreatic carcinoma. Curr Med Chem (2014) 1.01
Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways. Oncol Rep (2012) 1.01
The FOS transcription factor family differentially controls trophoblast migration and invasion. J Biol Chem (2013) 0.98
Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer. Cancer Res (2014) 0.96
Regulation of ceramide channels by Bcl-2 family proteins. FEBS Lett (2010) 0.92
Adjuvant therapy in pancreatic cancer. World J Gastroenterol (2014) 0.90
Mesenchymal stem cells promote liver regeneration and prolong survival in small-for-size liver grafts: involvement of C-Jun N-terminal kinase, cyclin D1, and NF-κB. PLoS One (2014) 0.90
Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation. J Cell Biochem (2013) 0.89
Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther (2014) 0.89
Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. Int J Oncol (2012) 0.89
Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia (2015) 0.87
ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells. PLoS One (2012) 0.86
A gemcitabine sensitivity screen identifies a role for NEK9 in the replication stress response. Nucleic Acids Res (2014) 0.86
Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways. Onco Targets Ther (2014) 0.86
Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. FEBS Lett (2005) 0.84
Roscovitine-induced apoptosis in neutrophils and neutrophil progenitors is regulated by the Bcl-2-family members Bim, Puma, Noxa and Mcl-1. PLoS One (2013) 0.83
Taxanes: impact on pancreatic cancer. Anticancer Drugs (2014) 0.83
Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol (2011) 0.82
Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer. Cancer Lett (2013) 0.79
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. Gynecol Oncol (2013) 0.79
Rhomboid domain containing 1 inhibits cell apoptosis by upregulating AP-1 activity and its downstream target Bcl-3. FEBS Lett (2013) 0.79
The effect of c-Fos demethylation on sodium fluoride-induced apoptosis in L-02 cells. Biol Trace Elem Res (2012) 0.79
Selective induction of apoptosis: promising therapy in pancreatic cancer. Curr Pharm Des (2013) 0.78